Abemaciclib + Pembrolizumab In Glioblastoma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04118036 |
|
Recruitment Status :
Withdrawn
(Safety concerns)
First Posted : October 7, 2019
Last Update Posted : December 14, 2021
|
Sponsor:
Dana-Farber Cancer Institute
Information provided by (Responsible Party):
Patrick Y. Wen, MD, Dana-Farber Cancer Institute
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
| Recruitment Status : | Withdrawn |
|---|---|
| Estimated Primary Completion Date : | December 1, 2023 |
| Estimated Study Completion Date : | December 1, 2024 |